FEMERISGenesisbiotech Group
Home About Us Collaborations Products Research Publications

About Us

FEMERIS is focused on the development of assays to detect antimicrobial resistance in bacterial, fungal, and parasitic infections associated with Obstetric and Gynecological infections, such as Group B Streptococcus, Methicillin Resistant Staphylococcus aureus (MRSA), Candida spp., and Trichomonas vaginalis. We try to understand microbial and immunological factors associated with recurrent and chronic bacterial vaginosis and vulvovaginal candidiasis. Additionally, we works towards the discovery of novel therapeutics by designing and performing high-through-put small molecule inhibitor screens against microbial pathogens in collaboration with Venenum Biodesign, L.L.C. and the development of engineered probiotics to maintain health vaginal and gastrointestinal environments.

 

Scott E. Gygax

Scott E. Gygax, Ph.D.
Managing Director

David W. Hilbert

David W. Hilbert, Ph.D.
Assistant Director

Jessica Schuyler

Jessica Schuyler, M.S.
Laboratory Manager

Natalie Barnett-Bernodat

Natalie Barnett-Bernodat, M.S.
Research Associate

Terry Paulish Miller

Terry Paulish Miller, M.S.
Research Associate

W. Lamar Smith

W. Lamar Smith, B.S.
Collaborative Research
Clinical Coordinator

Jessica Zimmerman

Jessica Zimmerman, B. S.
Research Associate

 

Latest News

7/14 - Genesis Biotechnology Group (GBG) sponsored a two-day symposium on June 18th and 19th entitled “The Vaginal Microbiome and Bacterial Vaginosis.” Read Full Story

7/14 - FEMERIS publication: Smith WL, Hedges S, Mordechai E, Adelson ME, Trama J, Gygax SE, Kaunitz AK, Hilbert DW. Cervical and vaginal flora is highly concordant with respect to bacterial vaginosis-associated organisms and commensal lactobacillus species in reproductive-aged women. J. Clin. Micrbiol. In Press.

7/14 - FEMERIS publication: Whaley S, Caudle K, Vermitsky J-P, Chadwick SG, Toner G, Barker K, Gygax SE, Rogers PD. UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob. Agents Chemother. In Press.

10/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Novel antifungal drug discovery based on targeting pathways regulating the fungal-conserved Upc2 transcription factor” accepted into the journal Antimicrobial Agents and Chemotherapy.

9/2013 - FEMERIS Director Dr. Scott Gygax presented work done by Research Associate Sean Chadwick in a poster entitled “Disruption of Gardnerella vaginalis biofilms with clindamycin and metronidazole” at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colorado.

8/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1” accepted into the journal Antimicrobial Agents and Chemotherapy.

5/2013 - FEMERIS Research Associates, Lamar Smith and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “Detection of epidemic USA300 community-associated MRSA strains using a single allele-specific PCR targeting a novel polymorphism of Staphylococcus aureus pbp3” accepted into the Journal of Clinical Microbiology.

1/2013 - FEMERIS Director Dr. Scott Gygax had a manuscript entitled, “Mixed vaginitis- more than coinfection and with therapeutic implications” accepted into the journal Current Infectious Disease Reports.

1/2013 - FEMERIS Research Associates, Jessica Schuyler and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “X-Plate Technology™: A new method for detecting fluconazole resistance in Candida species” accepted into the Journal of Medical Microbiology.